Update on Novartis and Ariad trials

As of Dec. 6, 2016 Novartis and Ariad announced research updates

In Phase III study by Novartis on Zykadia® (ceritinib) as a first-line treatment, they found a 45% reduction in the risk of disease progression. The study found a median progression free survival (PFS) of 16.6 months for all patients taking ceritinib, compared with 8.1 months for patients treated using just chemotherapy.  Also reported an ORR of 72.5%, compared with 26.7% for chemotherapy patients. Patients with no brain metastases had a median PFS of 26.3 months with Zykadia compared with 8.3 months for standard chemotherapy.

Ariad had positive info from a Phase I/II study and a pivotal trial studying brigatinib, in patients with brain metastases.  Patients with brain mets had an ORR was 53% in the Phase I/II trial, and the patients with brain mets had an ORR of 67% in the higher dose arm B of the ALTA trial. Median brain mets PFS in Arm B was 18.4 months.

http://www.genengnews.com/gen-news-highlights/novartis-and-ariad-separately-report-positive-alk-inhibitor-results/81253504

This entry was posted in Anaplastic Large-Cell Lymphomas, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply